Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma.
Wang, X., Blackaby, W., Allen, V., Chan, G.K.Y., Chang, J.H., Chiang, P.C., Diene, C., Drummond, J., Do, S., Fan, E., Harstad, E.B., Hodges, A., Hu, H., Jia, W., Kofie, W., Kolesnikov, A., Lyssikatos, J.P., Ly, J., Matteucci, M., Moffat, J.G., Munugalavadla, V., Murray, J., Nash, D., Noland, C.L., Del Rosario, G., Ross, L., Rouse, C., Sharpe, A., Slaga, D., Sun, M., Tsui, V., Wallweber, H., Yu, S.F., Ebens, A.J.(2019) J Med Chem 62: 2140-2153
- PubMed: 30715878 
- DOI: https://doi.org/10.1021/acs.jmedchem.8b01857
- Primary Citation of Related Structures:  
6NO9 - PubMed Abstract: 
Pim kinases have been targets of interest for a number of therapeutic areas. Evidence of durable single-agent efficacy in human clinical trials validated Pim kinase inhibition as a promising therapeutic approach for multiple myeloma patients. Here, we report the compound optimization leading to GDC-0339 (16), a potent, orally bioavailable, and well tolerated pan-Pim kinase inhibitor that proved efficacious in RPMI8226 and MM.1S human multiple myeloma xenograft mouse models and has been evaluated as an early development candidate.
Organizational Affiliation: 
Genentech, Inc. , 1 DNA Way , South San Francisco , California 94080 , United States.